A Tailored Electronic Survivorship Care Plan for Prostate Cancer Survivors: A Multicenter Randomized Controlled Trial.

IF 5.9 2区 医学 Q1 UROLOGY & NEPHROLOGY Journal of Urology Pub Date : 2025-04-01 Epub Date: 2024-12-20 DOI:10.1097/JU.0000000000004359
Jennifer M Jones, Andrew Matthew, Simon Tanguay, Celestia S Higano, Larry Goldenberg, Doris Howell, Manjula Maganti
{"title":"A Tailored Electronic Survivorship Care Plan for Prostate Cancer Survivors: A Multicenter Randomized Controlled Trial.","authors":"Jennifer M Jones, Andrew Matthew, Simon Tanguay, Celestia S Higano, Larry Goldenberg, Doris Howell, Manjula Maganti","doi":"10.1097/JU.0000000000004359","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Although the provision of a survivorship care plan (SCP) has been recommended after prostate cancer (PCa) treatment, there have been no randomized controlled trials to examine their impact. The objective of this study was to evaluate the effect of a tailored PCa-SCP intervention provided to early-stage PCa survivors.</p><p><strong>Materials and methods: </strong>A prospective, parallel 1:1 randomized controlled trial was conducted at 3 sites across Canada. Early-stage PCa survivors were randomized (n = 189; 64% response rate) to receive PCa-SCP intervention or usual care. Assessments were performed at baseline, 6 months, and 12 months. The primary outcome was change in patient activation (Patient Activation Measure-13); secondary outcomes included satisfaction with information, self-management support, prostate-specific quality of life, cancer worry, health care utilization, and health behaviors.</p><p><strong>Results: </strong>For the primary patient activation analyses, no significant group-by-time differences were detected. There were significant between-group differences in (1) satisfaction with information from baseline to 6 months (mean [95% CI]: 7.13 [5.53-8.71]; effect size [ES], 0.34; <i>P</i> < .001) and baseline to 12 months (4.91 [3.06, 7.06]; ES, 0.19; <i>P</i> < .001); (2) social integration and support from baseline to 6 months (mean [95% CI]: 0.16 [0.06-0.26]; ES, 0.25; <i>P</i> = .002); and (3) skill and technique acquisition from baseline to 6 months (mean [95% CI]: 0.12 [-0.02 to 0.24]; ES, 0.33; <i>P</i> = .05). No other group-by-time differences were detected.</p><p><strong>Conclusions: </strong>The PCa-SCP intervention did not have a significant effect on patient activation but did increase satisfaction with information and some aspects of self-management support. Although the benefits of the provision of an SCP alone remain unclear, the PCa-SCP intervention is likely a valuable tool that can be built upon as part of a comprehensive approach to enhance the quality of care for PCa survivors.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov Identifier: NCT03017456.</p>","PeriodicalId":17471,"journal":{"name":"Journal of Urology","volume":" ","pages":"407-416"},"PeriodicalIF":5.9000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Urology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/JU.0000000000004359","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/20 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: Although the provision of a survivorship care plan (SCP) has been recommended after prostate cancer (PCa) treatment, there have been no randomized controlled trials to examine their impact. The objective of this study was to evaluate the effect of a tailored PCa-SCP intervention provided to early-stage PCa survivors.

Materials and methods: A prospective, parallel 1:1 randomized controlled trial was conducted at 3 sites across Canada. Early-stage PCa survivors were randomized (n = 189; 64% response rate) to receive PCa-SCP intervention or usual care. Assessments were performed at baseline, 6 months, and 12 months. The primary outcome was change in patient activation (Patient Activation Measure-13); secondary outcomes included satisfaction with information, self-management support, prostate-specific quality of life, cancer worry, health care utilization, and health behaviors.

Results: For the primary patient activation analyses, no significant group-by-time differences were detected. There were significant between-group differences in (1) satisfaction with information from baseline to 6 months (mean [95% CI]: 7.13 [5.53-8.71]; effect size [ES], 0.34; P < .001) and baseline to 12 months (4.91 [3.06, 7.06]; ES, 0.19; P < .001); (2) social integration and support from baseline to 6 months (mean [95% CI]: 0.16 [0.06-0.26]; ES, 0.25; P = .002); and (3) skill and technique acquisition from baseline to 6 months (mean [95% CI]: 0.12 [-0.02 to 0.24]; ES, 0.33; P = .05). No other group-by-time differences were detected.

Conclusions: The PCa-SCP intervention did not have a significant effect on patient activation but did increase satisfaction with information and some aspects of self-management support. Although the benefits of the provision of an SCP alone remain unclear, the PCa-SCP intervention is likely a valuable tool that can be built upon as part of a comprehensive approach to enhance the quality of care for PCa survivors.

Trial registration: ClinicalTrials.gov Identifier: NCT03017456.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
为前列腺癌幸存者量身定制的电子生存护理计划:一项多中心随机对照试验。
目的:尽管在前列腺癌(PCa)治疗后推荐提供生存护理计划(SCP),但没有随机对照试验来检验其影响。本研究的目的是评估为早期前列腺癌幸存者提供量身定制的PCa- scp干预的效果。材料和方法:在加拿大3个地点进行前瞻性、平行1:1随机对照试验。早期前列腺癌幸存者随机分组(n = 189;(有效率64%)接受PCa-SCP干预或常规护理。在基线、6个月和12个月时进行评估。主要结局是患者激活的改变(患者激活测量-13);次要结局包括信息满意度、自我管理支持、前列腺特异性生活质量、癌症担忧、医疗保健利用和健康行为。结果:对于初始患者激活分析,没有发现明显的组-时间差异。(1)从基线到6个月的信息满意度组间差异显著(平均[95% CI]: 7.13 [5.53-8.71];效应量[ES], 0.34;P < 0.001)和基线至12个月(4.91 [3.06,7.06],ES, 0.19, P < 0.001);(2)从基线到6个月的社会整合和支持(平均[95% CI]: 0.16 [0.06-0.26];ES 0.25;P = .002);(3)从基线到6个月的技能和技术获得(平均[95% CI]: 0.12[-0.02至0.24];ES 0.33;P = 0.05)。没有检测到其他按时间分组的差异。结论:PCa-SCP干预对患者激活没有显著影响,但确实增加了对信息和自我管理支持某些方面的满意度。虽然单独提供SCP的益处尚不清楚,但PCa-SCP干预可能是一种有价值的工具,可以作为提高PCa幸存者护理质量的综合方法的一部分。试验注册:clinicaltrials.gov标识符:NCT03017456。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Journal of Urology
Journal of Urology 医学-泌尿学与肾脏学
CiteScore
11.50
自引率
7.60%
发文量
3746
审稿时长
2-3 weeks
期刊介绍: The Official Journal of the American Urological Association (AUA), and the most widely read and highly cited journal in the field, The Journal of Urology® brings solid coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of urology. This premier journal presents investigative studies on critical areas of research and practice, survey articles providing short condensations of the best and most important urology literature worldwide, and practice-oriented reports on significant clinical observations.
期刊最新文献
Urologic Oncology: Bladder, Penis, and Urethral Cancer and Basic Principles of Oncology. Intraoperative Tranexamic Acid in Radical Cystectomy: Impact on Bleeding, Thromboembolism, and Survival Outcomes. Spontaneous Resolution of Primary Obstructive Megaureter: Risk Stratification and Prediction Based on Early Sonographic Factors. Validation of Prognostic Models for Renal Cell Carcinoma Recurrence, Cancer-Specific Mortality, and All-Cause Mortality. Development and Validation of the Length, Segment, and Etiology Anterior Urethral Stricture Disease Staging System Using Longitudinal Urethroplasty Outcomes Data From the Trauma and Urologic Reconstructive Network of Surgeons.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1